Equities Analysts Issue Forecasts for Geron Q3 Earnings

Geron Corporation (NASDAQ:GERN) – Stock analysts at Wedbush dropped their Q3 2026 EPS estimates for shares of Geron in a research note issued on Wednesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q4 2026 earnings at $0.01 EPS.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $47.23 million during the quarter, compared to analysts’ expectations of $55.24 million. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.

GERN has been the topic of a number of other research reports. Needham & Company LLC reduced their target price on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Geron has a consensus rating of “Hold” and an average target price of $3.64.

Geron Price Performance

Geron stock opened at $1.07 on Thursday. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. The stock has a market cap of $682.68 million, a P/E ratio of -8.23 and a beta of 0.57. The company has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.35. Geron has a 12-month low of $1.04 and a 12-month high of $4.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GERN. Profund Advisors LLC increased its stake in Geron by 21.3% in the third quarter. Profund Advisors LLC now owns 213,466 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 37,535 shares during the last quarter. Candriam S.C.A. increased its stake in shares of Geron by 71.6% during the 3rd quarter. Candriam S.C.A. now owns 3,253,960 shares of the biopharmaceutical company’s stock valued at $4,458,000 after acquiring an additional 1,358,068 shares during the last quarter. Ballentine Partners LLC lifted its holdings in shares of Geron by 14.5% during the 3rd quarter. Ballentine Partners LLC now owns 93,971 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 11,887 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Geron during the third quarter worth approximately $171,000. Finally, SG Americas Securities LLC purchased a new position in Geron during the third quarter worth approximately $155,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.